baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

MERUS N.V. EO -,09/ NL0011606264 /

2024-06-14 3:29:01 PM	Chg. +1.5000	Volume	Bid9:45:10 PM	Ask9:58:53 PM	High	Low
53.0000EUR	+2.91%	0 Turnover: 0.0000	-Bid Size: -	-Ask Size: -	53.0000	53.0000

GlobeNewswire 06-10 Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as C...

GlobeNewswire 06-03 Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentati...

GlobeNewswire 06-02 Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 202...

GlobeNewswire 05-30 Merus Announces Pricing of Upsized Public Offering of Common Shares

GlobeNewswire 05-29 Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire 05-28 Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire 05-28 Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate...

GlobeNewswire 05-23 Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire 05-23 Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m...

GlobeNewswire 05-13 Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

GlobeNewswire 05-08 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 05-06 Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno fo...

GlobeNewswire 04-24 Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

GlobeNewswire 04-11 Black Diamond Therapeutics Announces Changes to Board of Directors

GlobeNewswire 04-08 Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expre...

GlobeNewswire 04-03 Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire 03-05 Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is...

GlobeNewswire 03-04 Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

GlobeNewswire 02-28 Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Up...

GlobeNewswire 01-31 Merus to Participate in Upcoming Investor Conferences

GlobeNewswire 2023-12-03 Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

GlobeNewswire 2023-11-26 Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

GlobeNewswire 2023-11-02 Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

GlobeNewswire 2023-11-01 Merus to Participate in Upcoming Investor Conferences

GlobeNewswire 2023-10-23 Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

MERUS N.V. EO -,09/ NL0011606264 /

If you wish to receive reply to your feedback, please provide your email address.